Skip to content

Pharma.Tips

Unlocking Pharma's Secrets: Your Ultimate Guide to Pharmaceutical Success!

  • Home
  • Publisher Disclosure
  • About Us
  • Contact

Tag: nitrosamines

  • Home
  • nitrosamines

Supplier nitrosamine control weak during regulatory inspection – FDA/EMA nitrosamine expectations

Weak Control of Supplier Nitrosamines During Regulatory Inspections: A Comprehensive Playbook The emergence of nitrosamines as potential impurities in pharmaceutical products has raised significant regulatory scrutiny. Both the FDA and…

Analytical method sensitivity questioned during supplier audit – preventing product recall

Preventing Product Recalls: Addressing Concerns Over Analytical Method Sensitivity in Supplier Audits In the pharmaceutical industry, ensuring the integrity of analytical methods used for raw material analysis is vital to…

Regulatory query on nitrosamines during supplier audit – inspection-ready justification

Effective Strategies for Addressing Regulatory Queries on Nitrosamines During Supplier Audits Nitrosamines in pharmaceuticals have emerged as a significant concern for manufacturers, regulators, and quality assurance professionals. Contamination of raw…

Regulatory query on nitrosamines during supplier audit – CAPA for nitrosamine findings

CAPA Playbook for Managing Nitrosamine Findings in Supplier Audits The emergence of nitrosamines in pharmaceutical manufacturing processes has raised significant regulatory concerns, especially during supplier audits. Actionable insights are critical…

Analytical method sensitivity questioned during submission support – risk mitigation and control strategy

Effectively Managing Concern Over Analytical Method Sensitivity During Submission Support As regulatory scrutiny intensifies, particularly regarding the sensitivity of analytical methods used in pharmaceutical manufacturing, organizations face significant challenges in…

Supplier nitrosamine control weak during ongoing surveillance – FDA/EMA nitrosamine expectations

Strengthening Supplier Nitrosamine Control During Ongoing Surveillance Nitrosamines have emerged as a significant concern in pharmaceutical manufacturing, particularly in relation to raw materials. As organizations strive to ensure compliance with…

Potential nitrosamine source identified during supplier audit – preventing product recall

Addressing Potential Nitrosamine Sources Uncovered in Supplier Audits With increasing scrutiny around nitrosamine impurities, manufacturers face growing pressure to ensure that their raw materials meet strict regulatory guidelines. A recent…

Risk mitigation plan inadequate during submission support – risk mitigation and control strategy

Effective Strategies for Inadequate Risk Mitigation During Submission Support In the evolving landscape of pharmaceutical manufacturing, ensuring rigorous risk management, particularly during submission support phases, is critical. An inadequate risk…

Nitrosamine risk assessment incomplete during ongoing surveillance – risk mitigation and control strategy

Navigating Incomplete Nitrosamine Risk Assessments During Ongoing Surveillance: A Practical Playbook Nitrosamines, particularly in pharmaceutical manufacturing, have emerged as critical components of risk assessment strategies due to regulatory pressures from…

Risk mitigation plan inadequate during regulatory inspection – CAPA for nitrosamine findings

Developing an Effective Risk Mitigation Plan for Nitrosamine Findings During Regulatory Inspections As the pharmaceutical industry navigates increasing scrutiny regarding nitrosamine contamination, professionals across manufacturing and quality sectors must ensure…

Supplier nitrosamine control weak during regulatory inspection – CAPA for nitrosamine findings

Enhancing Supplier Nitrosamine Control for Regulatory Inspections Nitrosamines pose a significant risk in pharmaceutical manufacturing, particularly concerning raw materials. A recent increase in regulatory scrutiny has revealed that many organizations…

Analytical method sensitivity questioned during ongoing surveillance – risk mitigation and control strategy

As pharmaceutical manufacturing operations intensify scrutiny due to evolving regulations and compliance landscapes, analytical method sensitivity has emerged as a critical concern. This issue is particularly acute in the context…

Posts pagination

1 2 … 14 Next

Quick Guide

  • Dosage Forms & Drug Delivery Systems
    • Solid Oral Dosage Forms (Tablets, Capsules)
    • Liquid Oral Dosage Forms (Syrups, Suspensions)
    • Parenteral Dosage Forms (Injectables)
    • Topical & Dermatological Dosage Forms
    • Ophthalmic Dosage Forms
    • Otic Dosage Forms
    • Inhalation & Nasal Dosage Forms
    • Transdermal Drug Delivery Systems
    • Rectal & Vaginal Dosage Forms
    • Dental Dosage Forms
    • Aerosol Formulations
    • Advanced & Novel Drug Delivery Systems
    • Miscellaneous / Combination Drug Products
  • Product Types & Therapeutic Categories
    • Active Pharmaceutical Ingredients (APIs)
    • Finished Pharmaceutical Products (FPPs)
    • Biologics
    • Biosimilars
    • Advanced Therapy Medicinal Products (ATMPs)
    • Oncology Products
    • Hormonal Products
    • Orphan Drugs
    • Radiopharmaceuticals
    • Controlled Substances & Schedule Drugs
    • Ophthalmic & Otic Products
    • Veterinary Medicines
    • Medical Devices
    • Nutraceuticals & Dietary Supplements
    • Herbal & Ayurvedic Products
    • Cosmetic & Cosmeceutical Products
  • Manufacturing Defects & Product Failures
    • Tablet Manufacturing Defects
    • Capsule Manufacturing Defects
    • Injectable Product Defects
    • Ointment & Cream Defects
    • Suspension & Syrup Defects
    • Dry Powder Inhaler (DPI) Defects
    • Transdermal Patch Defects
    • Primary Packaging Defects
    • Secondary & Tertiary Packaging Defects
    • Stability-Induced Product Defects
  • Deviation & Failure Case Studies
    • Manufacturing Deviation Case Studies
    • QC Laboratory Deviations
    • Environmental Monitoring Deviations
    • Sterility & Contamination Deviations
    • Data Integrity Breach Case Studies
    • Validation & Qualification Deviations
    • Warehouse & Storage Deviations
    • Packaging & Labeling Deviations
    • Cleaning & Cross-Contamination Deviations
    • Training & Documentation Deviations
  • Equipment & Instrumentation Troubleshooting
    • Tablet Compression Machine Issues
    • Capsule Filling Machine Issues
    • Granulation Equipment (FBD, RMG) Issues
    • Coating Equipment Problems
    • Filling Line Equipment Problems
    • Autoclave & Depyrogenation Tunnel Issues
    • Blister & Cartoning Machine Issues
    • Labeling & Printing Machine Faults
    • HPLC / GC / UHPLC Equipment Faults
    • HVAC & Cleanroom Troubleshooting
  • Process Optimization & Manufacturing Excellence
    • Compression Process Optimization
    • Granulation Process Optimization
    • Blending Uniformity Improvement
    • Capsule Filling Optimization
    • Solution & Suspension Preparation Optimization
    • Sterile Filtration & Filling Optimization
    • Drying Process Optimization (FBD, Tray Dryer)
    • Coating Efficiency & Uniformity
    • Yield Improvement Strategies
    • Cleaning Cycle Time Reduction
  • Functional Areas in Pharma Operations
    • Manufacturing & Production
    • Quality Assurance (QA)
    • Quality Control (QC)
    • Regulatory Affairs
    • Research & Development (R&D)
    • Validation & Qualification
    • Engineering & Maintenance
    • Packaging Development
    • Stability Studies
    • Supply Chain & Logistics
    • Clinical & Pharmacovigilance
    • Information Technology (IT)
    • Environment, Health & Safety (EHS)
    • Training & HR in GMP Environment
    • Intellectual Property Management (IPR)
    • Project Management
    • Corporate Compliance & Audit Readiness
  • Regulatory Compliance & Quality Systems
    • Good Manufacturing Practices (GMP)
    • WHO GMP Compliance
    • WHO Prequalification (PQ)
    • Good Laboratory Practices (GLP)
    • Good Clinical Practices (GCP)
    • Good Documentation Practices (GDP / ALCOA+)
    • Data Integrity Compliance
    • Validation & Qualification Compliance
    • Audit Readiness & Regulatory Inspections
    • Electronic Records & Electronic Signatures (ERES)
    • Quality Management System (QMS)
    • Regulatory Submissions & Dossiers
    • Serialization & Traceability
    • Import / Export Regulatory Compliance
    • Environmental, Health & Safety Regulations
    • ICH Guidelines & Global Frameworks
    • Controlled Substances Regulations
    • Medical Device Regulatory Compliance
  • Pharmaceutical Research & Drug Development
    • Drug Discovery
    • Preclinical Research
    • Pharmaceutical Research Methodologies
    • Formulation Development
    • Process Development
    • Scale-Up & Tech Transfer
  • Raw Materials & Excipients Management
    • API Quality & Variability Issues
    • Excipient Selection & Compatibility
    • Vendor Qualification & Audits
    • Raw Material Sampling Errors
    • Material Storage & Shelf-Life Control
    • Change Management for Raw Materials
    • Pharmacopoeial Compliance (USP/EP/IP)
    • Material Traceability & Mix-Up Prevention
    • Nitrosamine Risk in Raw Materials
  • Pharmaceutical Packaging Systems
    • Primary Packaging Material Selection
    • Container Closure Integrity (CCI)
    • Blister vs Bottle Packaging Decisions
    • Extractables & Leachables (E&L)
    • Child-Resistant & Senior-Friendly Packaging
    • Cold Chain Packaging Systems
    • Packaging for Sterile Products
    • Artwork Control & Regulatory Review
    • Packaging Line Design & Scale-Up
  • Cleaning, Contamination & Cross-Contamination Control
    • Cleaning Validation Fundamentals
    • Worst-Case Product Selection
    • Residue Limit Calculations (MACO)
    • Detergent Selection & Residue Control
    • Campaign Manufacturing Risks
    • Shared Facility Risk Management
    • Visual Inspection Failures
    • Swab vs Rinse Sampling Issues
    • Cleaning Deviations & CAPA
  • Data Integrity & Digital Pharma Operations
    • ALCOA+ Principles Explained Practically
    • Audit Trail Review Failures
    • Spreadsheet & Excel Data Integrity
    • LIMS Data Integrity Issues
    • CDS (Chromatography Data System) Risks
    • User Access & Privilege Control
    • Backup, Archival & Data Retention
    • Hybrid Paper–Electronic Systems
    • Data Integrity During Inspections
  • Validation, Qualification & Lifecycle Management
    • Process Validation Stage 1–3
    • Continued Process Verification (CPV)
    • Equipment Qualification Pitfalls
    • Utility Qualification (PW, WFI, HVAC)
    • Cleaning Validation Lifecycle
    • Analytical Method Validation Errors
    • Computer System Validation (CSV/CSA)
    • Revalidation Triggers & Strategy
    • Validation Documentation Best Practices
  • Stability Studies & Shelf-Life Management
    • Stability Study Design Errors
    • OOT & OOS in Stability Studies
    • Climatic Zone Considerations
    • Bracketing & Matrixing Misuse
    • Photostability Study Failures
    • Stability Trending & Statistical Analysis
    • Label Claim Justification
    • Ongoing Stability Program Gaps
    • Regulatory Expectations for Stability
  • Pharmaceutical Quality Systems (Advanced QMS)
    • QMS Design for GMP Compliance
    • Management Review Effectiveness
    • Quality Risk Management (ICH Q9)
    • Change Control System Failures
    • CAPA System Effectiveness
    • Deviation Trending & Metrics
    • Supplier Quality Management
    • Document Control System Design
    • Inspection Readiness Programs
  • Regulatory Inspections & Enforcement Actions
    • FDA Inspection Types & Strategy
    • Form 483 Observations Explained
    • Warning Letter Case Studies
    • Data Integrity Enforcement Trends
    • Consent Decrees & Import Alerts
    • Inspection Preparation Checklists
    • Inspector Interview Handling
    • Mock Audit Execution
    • Post-Inspection Remediation
  • Pharmaceutical Manufacturing Scale-Up & Tech Transfer
    • Lab to Pilot Scale Challenges
    • Pilot to Commercial Scale Risks
    • Tech Transfer Documentation
    • CMOs & CDMOs Tech Transfer
    • Process Robustness at Scale
    • Equipment Equivalency Issues
    • Site-to-Site Transfer Risks
    • Regulatory Filing Impact of Scale-Up
    • Post-Approval Change Management
  • Human Factors, Training & GMP Culture
    • GMP Training Effectiveness
    • Human Error in Manufacturing
    • SOP Design & Usability
    • Shift Handover Failures
    • Operator Qualification Programs
    • Training Documentation Gaps
    • Behavioral GMP Issues
    • Quality Culture Development
    • Management Accountability in GMP
  • Pharmaceutical Engineering & Utilities
    • HVAC Design for GMP Facilities
    • Cleanroom Classification Errors
    • Water Systems (PW/WFI) Issues
    • Compressed Air & Gas Quality
    • Preventive Maintenance Failures
    • Calibration System Weaknesses
    • Facility Layout & Material Flow
    • Utility Excursion Management
    • Engineering Change Control
  • Supply Chain, Warehousing & Distribution
    • GDP for Warehousing
    • Temperature Excursion Management
    • Cold Chain Failures
    • Distribution Qualification
    • Third-Party Logistics Oversight
    • Recall Readiness & Traceability
    • Serialization & Track-and-Trace
    • Import Export Compliance Issues
    • Warehouse Audit Findings
  • Pharma Audits, Risk & Compliance Strategy
    • Internal Audit Program Design
    • Risk-Based Audit Planning
    • Vendor & CMO Audits
    • Audit Observation Classification
    • Audit Response Writing
    • CAPA Risk Prioritization
    • Regulatory Intelligence & Trends
    • Compliance Governance Models
    • Corporate Quality Strategy
  • Emerging Technologies & Future Pharma Operations
    • Continuous Manufacturing
    • PAT & Real-Time Release Testing
    • AI & Automation in Pharma
    • Digital Twins in Manufacturing
    • Paperless GMP Systems
    • Advanced Analytics for Quality
    • Smart Factories & Pharma 4.0
    • Regulatory View on New Technologies
Copyright © 2026 Pharma.Tips Theme: Timely News By Artify Themes.